Nahom Seyoum

Dr. Nahom Seyoum

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2024 in Cancers
Verified
Journal Article
Open access
PDF file
STSteven Tohmasi
Steven Tohmasi
DJDaniel Eaton Jr
Daniel Eaton Jr
BHBrendan T. Heiden
Brendan T. Heiden
NRNIKKI ROSSETTI
NIKKI ROSSETTI
ABAna A. Baumann
Ana A. Baumann
VPVarun Puri
Varun Puri
Background: Socioeconomic deprivation has been associated with higher lung cancer risk and mortality in non-Veteran populations. However, the impact of socioeconomic deprivation on outcomes for non-small cell lung cancer (NSCLC) in an integrated and equal-access healthcare system, such as the Veterans Health Administration (VHA), remains unclear. Hence, we investigated the impact of area-level socioeconomic deprivation on access to care and postoperative outcomes for early-stage NSCLC in United States Veterans. Methods: We conducted a retrospective cohort study of patients with clinical stage I NSCLC receiving surgical treatment in the VHA between 1 October 2006 and 30 September 2016. A total of 9704 Veterans were included in the study and assigned an area deprivation index (ADI) score, a measure of socioeconomic deprivation incorporating multiple poverty, education, housing, and employment indicators. We used multivariable analyses to evaluate the relationship between ADI and postoperative outcomes as well as adherence to guideline-concordant care quality measures (QMs) for stage I NSCLC in the preoperative (positron emission tomography [PET] imaging, appropriate smoking management, pulmonary function testing [PFT], and timely surgery [≤12 weeks after diagnosis]) and postoperative periods (appropriate surveillance imaging, smoking management, and oncology referral). Results: Compared to Veterans with low socioeconomic deprivation (ADI ≤ 50), those residing in areas with high socioeconomic deprivation (ADI > 75) were less likely to have timely surgery (multivariable-adjusted odds ratio [aOR] 0.832, 95% confidence interval [CI] 0.732–0.945) and receive PET imaging (aOR 0.592, 95% CI 0.502–0.698) and PFT (aOR 0.816, 95% CI 0.694–0.959) prior to surgery. In the postoperative period, Veterans with high socioeconomic deprivation had an increased risk of 30-day readmission (aOR 1.380, 95% CI 1.103–1.726) and decreased odds of meeting all postoperative care QMs (aOR 0.856, 95% CI 0.750–0.978) compared to those with low socioeconomic deprivation. There was no association between ADI and overall survival (adjusted hazard ratio [aHR] 0.984, 95% CI 0.911–1.062) or cumulative incidence of cancer recurrence (aHR 1.047, 95% CI 0.930–1.179). Conclusions: Our results suggest that Veterans with high socioeconomic deprivation have suboptimal adherence to care QMs for stage I NSCLC yet do not have inferior long-term outcomes after curative-intent resection. Collectively, these findings demonstrate the efficacy of an integrated, equal-access healthcare system in mitigating disparities in lung cancer survival that are frequently present in other populations. Future VHA policies should continue to target increasing adherence to QMs and reducing postoperative readmission for socioeconomically disadvantaged Veterans with early-stage NSCLC.

10 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AKArvind Kumar
Arvind Kumar
STSteven Tohmasi
Steven Tohmasi
DJDaniel Eaton Jr
Daniel Eaton Jr
NSNahom Seyoum
Nahom Seyoum
WBWhitney S. Brandt
Whitney S. Brandt
BHBrendan T. Heiden
Brendan T. Heiden
Background: Recent clinical trials support adjuvant treatment with novel immunotherapy and targeted therapy agents for selected non-small-cell lung cancer (NSCLC) after resection. The “real-world” implementation of these treatments, however, remains unknown. This study evaluated trends in the uptake of adjuvant chemotherapy, immunotherapy, and targeted therapy for patients with resected NSCLC. Methods: Patients with resected stage IB-III NSCLC within the Veterans Health Administration (2017−2023) were included. Use of adjuvant chemotherapy, immunotherapy, and/or targeted therapy was evaluated over the study period. Factors associated with adjuvant therapy use were identified using multivariable-adjusted logistic regression. Results: Of the 1980 patients included, 846 (42.7%) underwent adjuvant therapy. There was a modest but not statistically significant increase in adjuvant therapy use from 37.1% in 2017 to 45.9% in 2023. Use of adjuvant chemotherapy alone declined from 36.6% to 23.5%, while use of adjuvant immunotherapy (0.5% to 21.2%) and targeted therapy (0% to 1.2%) increased. Factors associated with adjuvant therapy use included younger age, fewer comorbidities, and higher tumor stage. Conclusions: Despite the increased use of adjuvant immunotherapy and targeted therapy for resected stage IB-III NSCLC, overall adjuvant therapy uptake remains low. Further efforts will be necessary to better incorporate these novel treatments into routine clinical practice.

Verified
Journal Article
Open access
PDF file
PPPriya Patel
Priya Patel
AKAbigail Kim
Abigail Kim
MSMilana Shapsay
Milana Shapsay
SJShriya Jaddu
Shriya Jaddu
NSNahom Seyoum
Nahom Seyoum
JWJennifer A Walker
Jennifer A Walker
Background/Objectives: Spontaneous intraparenchymal hemorrhage (sIPH) accounts for a significant proportion of strokes and is associated with an estimated 30-day mortality between 35 and 52%. Subsequent hematoma progression (HP) occurs in up to 30% of patients and is associated with blood pressure variability, increasing poor outcomes. This study evaluates systolic blood pressure and heart rate variability in the emergency department (ED) and HP in the first 24 h of admission. Methods: This retrospective study analyzed patients with sIPH presenting to the ED and transferred to a resuscitation unit between 2017 and 2020. Outcomes included the occurrence of HP. Variables included blood pressure variability as measured by the standard deviation in systolic blood pressure (SBP-SD), successive variation of systolic blood pressure (SBP-SV), standard deviation of heart rate (HR-SD), and successive variation of heart rate (HR-SV). Bivariate analysis and machine learning algorithms were used to identify ED predictors for HP. Results: Of the 142 records analyzed, 41 (29%) patients experienced HP. The medians [interquartile (IQR)] for baseline characteristics were similar between groups. In the group with no HP (control), the median [IQR] for SBP-SD was 17.6 [11–26] compared with 20.5 [13.9–26.1, p = 0.25]. The median [IQR] for standard deviation in SBP-SV was 18 [11.4–25.4] for the control group and 19.8 [15.2–27.3, p = 0.19] for the HP group. While bivariate analysis did not show statistical difference for SBP-SD, SBP-SV, HR-SD, or HR-SV, machine learning algorithms identified SBP-SD, HR-SD, and HR-SV as clinically impactful on HP with good accuracy (92.59% and 79.31%). Conclusions: This study suggests that there are factors in hyperacute hemodynamic management in the ED associated with HP among patients with sIPH.

28 January 2026 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
AGAhmed Ghani
Ahmed Ghani
NSNahom Seyoum
Nahom Seyoum
DEDaniel B. Eaton
Daniel B. Eaton
SMSara Malone
Sara Malone
SCSu-Hsin Chang
Su-Hsin Chang
BHBrendan T. Heiden
Brendan T. Heiden
Phantom lymph node collection, defined as intraoperative sampling of tissue presumed to be nodal that, on pathologic review, proves to be non-nodal, is a previously understudied outcome in thoracic surgery. This study aimed to quantify its incidence, identify associated factors, and assess its relationship with cancer-specific outcomes. We conducted a retrospective cohort study using a meticulously curated Veterans Health Administration dataset of patients undergoing curative-intent non-small cell lung cancer resection between 2018 and 2024. Our primary outcomes included frequency of phantom lymph node collection, along with covariates independently associated with it. Secondary outcomes were overall survival and recurrence-free survival. A total of 2972 veterans were included in this cohort. Phantom lymph node collection occurred in 327 (11.0%) patients. On multivariable analysis, phantom lymph node collection was more likely with lower-lobe tumors (odds ratio, 1.45; 95% CI, 1.13-1.88), and less likely among patients who received guideline-concordant nodal sampling (≥3 N2 and ≥1 N1 nodal stations) (odds ratio, 0.56; 95% CI, 0.43-0.74). Notably, phantom lymph node collection was not associated with overall (hazard ratio, 0.96; 95% CI, 0.77-1.19) or recurrence-free survival (hazard ratio, 0.86; 95% CI, 0.68-1.08). Phantom lymph node collection is common during curative-intent resection of early-stage lung cancer. Although not prognostic, its association with guideline-concordant sampling highlights it as a potential target for surgical quality improvement initiatives.

27 August 2025 in The Annals of Thoracic Surgery
Verified
Journal Article
Open access
NSNahom Seyoum
Nahom Seyoum
DEDaniel B. Eaton
Daniel B. Eaton
STSteven Tohmasi
Steven Tohmasi
NRNikki Rossetti
Nikki Rossetti
SCSu-Hsin Chang
Su-Hsin Chang
BHBrendan T. Heiden
Brendan T. Heiden
Previous studies assessing quality of care among patients undergoing surgery for non-small cell lung cancer (NSCLC) have largely focused on preoperative and perioperative process-based quality measures. This study sought to address this knowledge gap by studying the association between postoperative (ie, survivorship) quality metrics (QMs) and cancer-specific outcomes. Using a unique Veterans Health Administration data set, study investigators performed a retrospective cohort study including patients with early-stage NSCLC treated surgically. On the basis of contemporary guidelines, 3 QMs were defined: appropriate surveillance imaging, comprehensive smoking cessation management, and appropriate referral to oncology (only for tumors >3 cm). The study assessed the relationship between QM adherence and overall survival (OS) and the cumulative incidence of cancer recurrence (CIR). Between 2006 and 2016, 8137 patients were included in the study. Among patients with tumors ≤3 cm, better adherence to QMs was associated with improved OS (5-year survival; 0 QM, 50.5%; 1 QM, 61.9%; 2 QMs, 66.9%; P < .001) and decreased CIR (5-year cumulative incidence; 0 QM, 49.2%; 1 QM, 21.8%; 2 QMs, 12.2%; P < .001). Among patients with tumors >3 cm (n = 1702,), better adherence to QMs was associated with improved OS (5-year survival; 0 QM, 44.9%; 1 QM, 49.2%; 2 QMs, 55.9%; 3 QMs, 63.8%; P < .001) and decreased CIR (5-year cumulative incidence; 0 QM, 61.3%; 1 QM, 40.7%; 2 QMs, 27.0%; 3 QMs, 13.7; P < .001). Adherence to survivorship QMs is associated with dramatically improved cancer-specific outcomes among patients with early-stage NSCLC after surgical treatment. Efforts to standardize survivorship care pathways may significantly improve long-term outcomes among patients undergoing curative-intent resection.

11 February 2026 in Surgery
Verified
Journal Article
Open access
NSNahom Seyoum
Nahom Seyoum
STSteven Tohmasi
Steven Tohmasi
DEDaniel B. Eaton
Daniel B. Eaton
TLTullis Liu
Tullis Liu
NRNikki E. Rossetti
Nikki E. Rossetti
VPVarun Puri
Varun Puri
Although surgical resection is the standard of care for early-stage non-small cell lung cancer, frailty influences treatment decisions. We evaluated the prognostic utility of the Veterans Affairs Frailty Index, a claims-based assessment tool, among veterans undergoing resection for stage I non-small cell lung cancer. We conducted a retrospective cohort study of veterans who underwent curative-intent surgery for stage I non-small cell lung cancer in the Veterans Health Administration from 2006 to 2020. Using the Veterans Affairs Frailty Index, frailty was categorized as follows: nonfrail (≤0.1), prefrail (0.1-0.2), mildly frail (0.2-0.3), moderately frail (0.3-0.4), and severely frail (>0.4). The primary outcome was overall survival, assessed using multivariable Cox regression. Secondary outcomes included major complications, prolonged hospitalization, 30-day readmission, 90-day mortality, and recurrence. Among 12,271 veterans, 7.7% were severely frail. Compared with nonfrail patients, severely frail patients were older (mean age 70.3 years vs 64.7 years; P < .001) and were more likely to undergo minimally invasive surgery (57.7% vs 37.8%) and sublobar resection (41.2% vs 22.3%) (all P < .001). Severe frailty was independently associated with higher risk of major complications (adjusted odds ratio 2.85, 95% confidence interval 2.18-3.71), prolonged hospitalization (adjusted odds ratio 2.67), 30-day readmission (adjusted odds ratio 1.76), 90-day mortality (adjusted odds ratio 2.87), and worse overall survival (adjusted hazard ratio 2.20, 95% confidence interval 1.97-2.46; all P < .001). Recurrence was not significantly associated with frailty (adjusted hazard ratio 0.87; P = .410). Frailty, as measured by the Veterans Affairs Frailty Index, independently predicts adverse postoperative and survival outcomes following resection for stage I non-small cell lung cancer. Preoperative frailty assessment may improve risk stratification and guide surgical decision making.